Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ferric Ammonium Citrate→

Ferric Ammonium Citrate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1185-57-5
Molecular formula
C6H11FeNO7+3
Molecular weight
265 g/mol
Drug class
Ferric ammonium citrate complexoral iron source and nutritional iron supplement
Mechanism of action
Provides ferric iron that is reduced and absorbed through intestinal iron-uptake pathways, then incorporated into transferrin, haemoglobin and iron stores. Citrate and ammonium are complexing/counter-ion components.
Indications / reported uses
  • Treatment or prevention of iron deficiency and iron-deficiency anaemia in authorised oral iron preparations; indications and elemental iron dose depend on the formulation and product label

Sources: PubChem — Ferric ammonium citrate · NIH Office of Dietary Supplements — Iron fact sheet · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ferric Ammonium Citrate Environmental Risk Assessment (ERA) (the Ferric Ammonium Citrate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.